bioAffinity Technologies, Inc. BIAF
bioAffinity Technologies, Inc. (Nasdaq: BIAF) is an oncology diagnostics company. Its next catalyst on record is CyPath Lung longitudinal clinical trial: Patient enrollment and trial progress (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CyPath Lung longitudinal clinical trial — Patient enrollment and trial progress (date not stated). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Lung inflammation diagnostic for asthma/COPD | precision diagnostics for asthma and COPD | flow cytometry and ELISA | Pre-clinical |
| Self-delivering siRNAs (OncoSelect Therapeutics) | squamous cell skin cancer | RNA (siRNA) | Pre-clinical |
| CyPath Lung | early detection of lung cancer | flow cytometry platform | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 1, 2026positive The Company presented positive research results at CHEST 2026 relating to its development of noninvasive tests to characterize lung inflammation in asthma and COPD.
The Company presented positive research results at CHEST 2026 relating to its development of noninvasive tests to characterize lung inflammation and investigate biologic drug targets for asthma and COPD therapies.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
- Legend Biotech Corp LEGN
- Veracyte, Inc. VCYT
- Indaptus Therapeutics, Inc. INDP
- SL Science Holding Ltd SLBT
- YD Bio Ltd YDES
- OnKure Therapeutics, Inc. OKUR
- Boundless Bio, Inc. BOLD
- NextCure, Inc. NXTC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.